ArQule RSS Feed | Nachrichten | finanzen.netwww.finanzen.net bietet Finanznachrichten zum weltweiten Boersengeschehenhttp://www.finanzen.netde-deSmartHouse Media GmbHhttp://finanzen.net/images/finanzen_net.gifFinanzen.nethttp://www.finanzen.netArQule Announces Appointment of Brian Schwartz as Chief Medical Officerhttp://www.finanzen.net/nachricht/ArQule_Announces_Appointment_of_Brian_Schwartz_as_Chief_Medical_Officer_743989ArQule, Inc. (Nasdaq: ARQL) today announced the appointment of Brian Schwartz, M.D., as chief medical officer effective July 14, 2008. Dr. Schwartz brings to ArQule significant experience in oncology drug development in both ...http://www.finanzen.net/nachricht/ArQule_Announces_Appointment_of_Brian_Schwartz_as_Chief_Medical_Officer_743989ArQule, Inc. to Present at Seventh Annual Needham & Company Biotechnology and Medical Technology Conferencehttp://www.finanzen.net/nachricht/ArQule_Inc_to_Present_at_Seventh_Annual_Needham__Company_Biotechnology_and_Medical_Technology_Conference_737494ArQule, Inc. (Nasdaq: ARQL) today announced that it will present at the Seventh Annual Needham & Company Biotechnology and Medical Technology Conference on Thursday, June 12, 2008 at 2:00 p.m. eastern time. ArQule’s presentation ...http://www.finanzen.net/nachricht/ArQule_Inc_to_Present_at_Seventh_Annual_Needham__Company_Biotechnology_and_Medical_Technology_Conference_737494Data Presented at ASCO Identify Maximum Tolerated Dose and Confirm c-Met Inhibition in Tumors with ARQ 197, Under Development by ArQulehttp://www.finanzen.net/nachricht/Data_Presented_at_ASCO_Identify_Maximum_Tolerated_Dose_and_Confirm_c_Met_Inhibition_in_Tumors_with_ARQ_197_Under_Development_by_ArQule_734404Investigators today presented data from a Phase 1, dose-escalation trial with ARQ 197, a selective inhibitor of the c-Met receptor tyrosine kinase under development by ArQule, Inc. (NASDAQ: ARQL). These data demonstrate that the compound ...http://www.finanzen.net/nachricht/Data_Presented_at_ASCO_Identify_Maximum_Tolerated_Dose_and_Confirm_c_Met_Inhibition_in_Tumors_with_ARQ_197_Under_Development_by_ArQule_734404ArQule Reports First Quarter 2008 Financial Resultshttp://www.finanzen.net/nachricht/ArQule_Reports_First_Quarter_2008_Financial_Results_723310ArQule, Inc. (NASDAQ:ARQL) today announced its financial results for the first quarter of 2008. For the quarter ended March 31, 2008, the Company reported a net loss of $13,914,000 or $0.32 per share, compared to a net loss of ...http://www.finanzen.net/nachricht/ArQule_Reports_First_Quarter_2008_Financial_Results_723310ArQule, Inc. to Report First Quarter 2008 Financial Results on Monday, May 12, 2008http://www.finanzen.net/nachricht/ArQule_Inc_to_Report_First_Quarter_2008_Financial_Results_on_Monday_May_12_2008_718952ArQule, Inc. (NASDAQ: ARQL) today announced that it will report its financial results for the first quarter of 2008 in a press release to be issued on Monday, May 12, 2008 at 7:00 a.m. eastern time. The Company will host a conference ...http://www.finanzen.net/nachricht/ArQule_Inc_to_Report_First_Quarter_2008_Financial_Results_on_Monday_May_12_2008_718952ArQule, Inc. to Present at Leerink Swann Cancer Roundtable on May 9, 2008http://www.finanzen.net/nachricht/ArQule_Inc_to_Present_at_Leerink_Swann_Cancer_Roundtable_on_May_9_2008_718237ArQule, Inc. (Nasdaq: ARQL) today announced that it will present at the Leerink Swann Cancer Roundtable Conference on Friday, May 9, 2008 at 10:30 a.m.. ArQule’s presentation will be web cast live and can be accessed through the investor ...http://www.finanzen.net/nachricht/ArQule_Inc_to_Present_at_Leerink_Swann_Cancer_Roundtable_on_May_9_2008_718237ArQule Provides Clinical Update on E2F-1 Programhttp://www.finanzen.net/nachricht/ArQule_Provides_Clinical_Update_on_E2F_1_Program_706498ArQule, Inc. (NASDAQ: ARQL) today announced the completion of its previously disclosed analysis of QTc prolongation data related to a Phase 1 dose escalation trial with ARQ 171, a second generation product in its E2F-1 DNA damage ...http://www.finanzen.net/nachricht/ArQule_Provides_Clinical_Update_on_E2F_1_Program_706498ArQule Announces Receipt of Milestone Payment from Wyethhttp://www.finanzen.net/nachricht/ArQule_Announces_Receipt_of_Milestone_Payment_from_Wyeth_698077ArQule, Inc. (NASDAQ: ARQL) today announced the receipt of a milestone payment from Wyeth (NYSE:WYE) in connection with the filing of an Investigational New Drug (IND) application by Wyeth to the U.S. Food and Drug Administration ...http://www.finanzen.net/nachricht/ArQule_Announces_Receipt_of_Milestone_Payment_from_Wyeth_698077ArQule Enrolls First Patient in Phase 1/2 Clinical Trial Program of ARQ 197 in Non-Small Cell Lung Cancerhttp://www.finanzen.net/nachricht/ArQule_Enrolls_First_Patient_in_Phase_1_2_Clinical_Trial_Program_of_ARQ_197_in_Non_Small_Cell_Lung_Cancer_692471ArQule, Inc. (NASDAQ: ARQL) today announced the commencement of patient dosing in a Phase 1/2 clinical trial program of ARQ 197 administered in combination with erlotinib in patients with advanced non-small cell lung cancer (NSCLC). ...http://www.finanzen.net/nachricht/ArQule_Enrolls_First_Patient_in_Phase_1_2_Clinical_Trial_Program_of_ARQ_197_in_Non_Small_Cell_Lung_Cancer_692471ArQule, Inc. to Present at Susquehanna Financial Group Conference on March 5, 2008http://www.finanzen.net/nachricht/ArQule_Inc_to_Present_at_Susquehanna_Financial_Group_Conference_on_March_5_2008_683789ArQule, Inc. (Nasdaq: ARQL) today announced that it will present at the Susquehanna Financial Group’s Second Annual SIGnificant Options in Healthcare Conference on March 5, 2008 at 11:00 a.m. eastern time. ArQule’s presentation will ...http://www.finanzen.net/nachricht/ArQule_Inc_to_Present_at_Susquehanna_Financial_Group_Conference_on_March_5_2008_683789